NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded with an addition of $0.05 to close at $0.73 on Friday, an upside of 8.72 percent. An average of 4,439,617 shares of common stock have been traded in the last five days. There was a fall of -$0.5500 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 3,428,954 shares traded, while the 50-day average volume stands at 4,419,838.
NRBO stock has decreased by -57.27% in the last month. The company shares reached their 1-month lowest point of $0.5510 on 12/28/22. With the stock rallying to its 52-week high on 09/13/22, shares of the company touched a low of $0.55 and a high of $63.85 in 52 weeks. It has reached a new high 3 times so far this year and lost -98.16% or -$35.8600 in price. In spite of this, the price is down -98.85% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
NeuroBo Pharmaceuticals Inc. (NRBO) stock’s beta is -0.22. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.10.
The quick ratio of NeuroBo Pharmaceuticals Inc. for the three months ended September 29 was 4.70, and the current ratio was 4.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $14000.0 compared to revenue of $15.3 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, NeuroBo Pharmaceuticals Inc.’s return on assets was -115.80%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$3.11 million in the quarter, while revenues of -$3.3 million were shrunk -11.25%. The analyst consensus anticipated NeuroBo Pharmaceuticals Inc.’s latest quarter earnings to come in at -$5.4 per share, but it turned out to be -$4.8, a 11.10% surprise. For the quarter, EBITDA amounted to -$3.1 million. At the end of the quarter ending September 29, NeuroBo Pharmaceuticals Inc.’s stock balance sheet showed total liabilities of 1.62 million. Shareholders own equity worth $6.5 million.
From a technical analysis perspective, let’s take a brief look at NeuroBo Pharmaceuticals Inc. (NRBO) price momentum. RSI 9-day as of the close on 29 December was 26.37%, suggesting the stock is oversold, with historical volatility in this time frame at 239.06%.
As of today, NRBO’s price is $0.7497 -42.64% or -$0.5500 from its 5-day moving average. NRBO is currently trading -48.25% lower than its 20-day SMA and -93.77% lower than its 100-day SMA. However, the stock’s current price level is -93.86% below the SMA50 and -96.79% below the SMA200.
The stochastic %K and %D were 10.23% and 7.51%, respectively, and the average true range (ATR) was 0.2184. With the 14-day stochastic at 16.45% and the average true range at 0.3235, the RSI (14) stands at 29.56%. The stock has reached -0.2936 on the 9-day MACD Oscillator while the 14-day reading was at -0.4972.
H.C. Wainwright launched coverage on NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) in its analyst report released on June 15, 2020. The firm assigned the stock a Buy rating. The consensus rating for NeuroBo Pharmaceuticals Inc. (NRBO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NRBO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.